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Abstract: Pulmonary benign metastasizing leiomyoma (BML) occurs predominantly in women of reproductive age 
and usually develops several years after the resection of uterine leiomyoma. There is no standardized treatment 
for pulmonary BML owing to its low incidence. In this study, we retrospectively analyzed 11 patients with pulmonary 
BML. Major symptoms, imaging findings, therapeutic modalities, and outcomes were analyzed. The median patient 
age was 51 years (range, 45-65 years). All patients had uterine leiomyoma, for which all but one patient received 
myomectomy or hysterectomy. The preoperative symptoms included chest pain and coughing in four (36.4%) pa-
tients. In eight (72.7%) patients, computed tomography can revealed bilateral, multiple pulmonary nodules. The 
interval between the surgery for uterine leiomyoma and the diagnosis of pulmonary BML ranged from 13 months 
to 19 years. Thoracoscopic wedge resection was performed for two patients with unilateral pulmonary tumors. 
Therapeutic modalities included bilateral salpingo-oophorectomy, gonadotropin-releasing hormone agonist, aroma-
tase inhibitor, progestin, and tamoxifen. All but one patient is alive to date; the patient who received no treatment 
died of respiratory failure due to rapid progression of pulmonary BML. Our data for an unselected group of patients 
with pulmonary BML treated at a single institution are consistent with results from previous studies indicating that 
pulmonary BML is best managed with metastasectomy and/or a combination of surgery and hormonal therapy.
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Introduction
Uterine leiomyomas are the most common 
benign gynecological neoplasms in women of 
reproductive age. Rarely, it shows unusual 
growth patterns with extrauterine smooth mus-
cle nodules that seem to be derived from a 
benign uterine leiomyoma. Metastasis com-
monly follows surgical treatment by myomecto-
my or hysterectomy for uterine leiomyomas [1]. 
Benign metastasizing leiomyoma (BML) is a 
very rare disease that has been reported in 
association with uterine leiomyoma. The term 
BML is used to describe the presence of benign 
smooth muscle tumors in an organ distant from 
the uterus [2]. Since Steiner’s report in 1939 
[3], approximately 90 cases of BML have been 
reported in the literature. However, a unified 
perspective has not emerged regarding the bio-
logical nature, pathogenesis, or prognosis of 
this disease, because nearly all previous stud-
ies were case reports. Furthermore, no stan-
dardized treatment has been established for 
BML.
The lungs are the most common site of metas-
tasis for uterine leiomyoma, with characteristic 
scattered, bilateral nodules [4-6]. Data on the 
clinical behaviors, treatment, and patient out-
comes for pulmonary BML are also rare. Even 
the necessity of surgery for this metastatic 
lesion remains controversial. In this report, we 
provide data on 11 patients with newly diag-
nosed pulmonary BML treated at a single insti-
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tution over a 15-year period. We retrospectively 
analyzed the data in this series in order to 
determine significant clinical features that may 
affect the diagnosis and treatment of this 
disease.
Patients and methods
Patients and tissue specimens
We retrospectively analyzed all 11 patients who 
were consecutively diagnosed with histologi-
cally confirmed pulmonary BML and treated at 
the Samsung Medical Center between January 
2000 and December 2014. Patient character-
istics, including age, surgical treatment for 
uterine leiomyoma, respiratory symptoms, 
imaging findings, medical and/or surgical treat-
ment for pulmonary BML, the presence of sec-
ondary metastasis to other organs, and follow-
up period and outcome, were obtained through 
medical chart review. Surgical treatments for 
pulmonary BML included video-assisted thora-
coscopic surgery (VATS) wedge resection or 
lobectomy of the lungs and bilateral salpingo-
oophorectomy (BSO). Medical management 
included aromatase inhibitors (AI; anastrozole 
and letrozole), gonadotropin-releasing hormo- 
ne agonists (GnRHa; triptorelin, leuprorelin, 
buserelin, and goserelin), progesterone, and 
selective estrogen receptor modulators (SERM; 
tamoxifen, raloxifene, and toremifene).
Histopathological examination
The resected specimens at the Samsung 
Medical Center were fixed in 10% neutral-buff-
ered formalin and embedded in paraffin blocks. 
From each formalin-fixed, paraffin-embedded 
(FFPE) block, 4-μm sections were cut and 
stained with hematoxylin and eosin (H&E), and 
prepared for immunohistochemical staining. All 
H&E-stained slides were examined under rou-
tine light microscopy by gynecologic and pulmo-
nary pathologists.
Immunohistochemistry
Immunohistochemical staining was performed 
on the FFPE tissue sections, using a Bond-maX 
automated immunostainer (Leica Biosystems, 
Melbourne, Australia) and a Bond Polymer 
Refined Detection Kit (Leica Biosystems). The 
details of the primary antibodies used are sum-
marized in Table 1. Briefly, antigen retrieval was 
performed at 97°C for 20 min in ER1 or ER2 
buffer. After blocking endogenous peroxidase 
activity with 3% hydrogen peroxide for 10 min, 
primary antibody incubation was performed for 
15 min at room temperature. To verify antibody 
specificity, anti-mouse immunoglobulin was 
used instead of the primary antibody as a nega-
tive control.
Results
Clinical findings
Clinical characteristics and outcomes for the 
11 patients with pulmonary BML are summa-
rized in Table 2. The median patient age was 51 
years (mean, 52.2; range, 45-65 years), with 
nine (81.8%) patients younger than 55 years of 
age. Three (27.3%) patients were postmeno-
pausal. Seven (63.6%) patients did not have 
any respiratory symptoms. The major symptom 
was chest pain, occurring in three (27.2%) 
patients (Patients 1, 2, and 8). Other symptoms 
included a sensation of chest tightness (Patient 
1), hemoptysis (Patient 2), cough (Patient 8), 
and fever (Patient 8). All but one patient (Pati- 
ent 11) underwent surgery for uterine leiomyo-
mas. Six (54.5%) and four (36.4%) patients 
received total hysterectomy and myomectomy, 
respectively. Eight (72.7%) patients had multi-
ple, variable-sized leiomyomatous nodules in 
the uterus. The mean tumor size of the uterine 
leiomyoma was 5.4 cm (range, 2-16 cm). The 
interval between the surgery for uterine leio-
myoma and the diagnosis of pulmonary BML 
ranged from 13 months to 19 years (mean, 8 
Table 1. Antibodies used for immunohistochemical staining
Antibody Source Clone Dilution
SMA Dako, Agilent Technologies, Inc., Carpinteria, CA, USA 1A4 1:1,000
ER Thermo Fisher Scientific Inc., Fremont, CA, USA SP1 1:100
PR Dako, Agilent Technologies, Inc., Carpinteria, CA, USA PgR 636 1:50
TTF-1 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA 8G7G3/1 1:100
Ki-67 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA MIB-1 1:50
SMA: smooth muscle actin; ER: estrogen receptor; PR: progesterone receptor; TTF-1: thyroid transcription factor-1.
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Table 2. Clinical characteristics and outcomes of 11 patients with pulmonary BML
Patient 
No Age MP
Surgical Tx 
for UL
Interval  
between the Dx 
of UL and BML
Respiratory symptoms CT findings Surgical Tx for BML Medical Tx for BML
Recurrence 
or secondary 
metastasis
F/U period 
after the  
Dx of BML
Current 
status
1 47 No No 8 y 5 m Chest pain and tightness Unilateral, solitary nodule (2.0 cm) VATS WR No No 2 y 1 m NED
2 65 Yes Hysterectomy 19 y Chest pain and hemoptysis Unilateral, multiple nodules VATS WR and lobectomy No Pelvic wall 6 y 2 m SD
3 48 No Hysterectomy 2 y 5 m Absent Unilateral, solitary nodule (1.3 cm) BSO AI No 4 m SD
4 54 Yes Hysterectomy 11 y Absent Bilateral, multiple nodules BSO AI No 6 y 4 m SD
5 45 No Myomectomy 5 y Absent Bilateral, multiple nodules BSO GnRHa No 3 y 2 m SD
6 51 No Hysterectomy 5 y Absent Bilateral, multiple nodules BSO AI and GnRHa No 4 y SD
7 53 No Hysterectomy 11 y Absent Bilateral, multiple nodules BSO Progesterone No 5 y 8 m SD
8 59 Yes Myomectomy 3 y 5 m Cough and fever Bilateral, multiple nodules No AI No 1 y 2 m SD
9 49 No Myomectomy 1 y 1 m Absent Bilateral, multiple nodules No AI No 3 y 10 m SD
10 53 No Hysterectomy 12 y Absent Bilateral, multiple nodules No SERM No 4 y 11 m SD
11 50 No Myomectomy 8 y Chest pain Bilateral, multiple nodules No No No 8 m DOD
MP: menopause; Tx: treatment; UL: uterine leiomyoma; Dx: diagnosis; BML: benign metastasizing leiomyoma; y: year; m: month; CT: computed tomography; VATS: video-assisted thoracoscopic surgery; WR: wedge resection; BSO: bilateral 
salpingo-oophorectomy; AI: aromatase inhibitor; GnRHa: gonadotropin-releasing hormone agonist; SERM, selective estrogen receptor modulator; F/U: follow-up; NED: no evidence of disease; SD: stable disease; DOD: dead of tumor-related 
disease.
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years; median, 8 years). Chest computed tomo- 
graphy (CT) was the primary diagnostic method 
and we found either single or multiple nodular 
lesions on the CT images of all patients. In two 
(18.1%) patients, CT revealed a single, spheri-
cal, well-circumscribed pulmonary nodule in 
the right middle lobe, measuring 1.3 cm 
(Patient 3; Figure 1A) and 2.0 cm (Patient 1; 
Figure 1B), respectively. Patient 2 had unilat-
eral but multiple pulmonary nodules. The 
remaining eight (72.7%) patients had numer-
ous, variable-sized pulmonary nodules, which 
were scattered throughout both lungs (Figure 
1C-F). The pulmonary tumor size ranged from 
0.6 cm to 8.0 cm (mean, 2.4 cm). In 10 (90.9%) 
patients, VATS biopsy was performed to con-
Figure 1. Imaging findings of pulmonary BML. (A) Patient 3. Chest CT reveals a 1.3-cm single, well-circumscribed 
nodule (white arrow) in the right middle lobe. (B) Patient 1. A 2.0-cm single, spherical nodular lesion (white arrow) is 
noted in the right middle lobe. (C-F) There are multiple, round, well-circumscribed and variable-sized nodules (white 
arrows) in both lungs. (C. Patient 5; D. Patient 7; E. Patient 8; F. Patient 10).
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firm the diagnosis of BML histopathologically. 
The remaining patient was diagnosed with pul-
monary BML by ultrasonography-guided percu-
taneous needle biopsy.
Two patients, one who had a single pulmonary 
nodule (Patient 1) and one with unilateral, mul-
tiple nodules (Patient 2), received VATS wedge 
resection and VATS wedge resection with lobec-
Figure 2. Representative H&E-stained sections (A-C) and immunohistochemical findings for pulmonary BML (D-G). 
(A) A well-circumscribed pulmonary tumor consists of abundant smooth muscle cells, which surround scattered 
glandular structures (black arrows). (B) The spindle-shaped smooth muscle cells are arranged in interlacing fas-
cicles and whorls. The bronchial epithelial cells are entrapped within the tumor. (C) The smooth muscle cells display 
no cytologic atypia or mitotic figures. Immunohistochemically, strong nuclear positivity for (D) ER and (E) PR and 
cytoplasmic positivity for (F) SMA, together with (G) the absence of TTF-1 immunoreactivity, in the smooth muscle 
cells suggests that the tumor cells originated in the uterus. The entrapped bronchiolar epithelial cells serve as the 
internal control for TTF-1 immunostaining.
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tomy, respectively. The tumor of Patient 2 was 
not removed completely, but no further treat-
ment was performed. Patient 3 received BSO 
and AI therapy for a single lesion. Four (36.4%) 
of eight patients who developed bilateral, mul-
tiple pulmonary nodules received BSO and 
adjuvant medical treatment with AI, GnRHa, 
and/or progesterone, and three (27.3%) pati- 
ents received AI or SERM only. The remaining 
patient (Patient 11) refused surgical resection 
or medical treatment for bilateral, multiple 
BML. Her disease rapidly progressed, and she 
died of respiratory failure due to extensive 
tumor involvement 8 months after the diagno-
sis of BML.
Clinical outcomes
Median follow-up was 46 months. One (9.1%) 
patient died during the study period (between 
2000 and 2014). Nine (90.9%) patients were 
alive at the last follow-up and the presence of 
stable pulmonary lesions was monitored with 
sequential CT scans. In these patients, the size 
of the nodules decreased slightly during the 
medical treatment and no newly developed 
lesions were observed, and the disease status 
was evaluated as stable according to the 
“Response Evaluation Criteria In Solid Tumors” 
criteria. The remaining patient had no evidence 
of disease at the time of analysis. One patient 
developed recurrent leiomyoma in the pelvic 
wall after surgery but received no further treat-
ment. No severe treatment complications were 
documented.
Histopathological findings
Histopathological examination of wedge-re- 
sected specimens revealed isolated, unencap-
sulated, solid nodules that were sharply demar-
cated from the adjacent pulmonary parenchy-
ma (Figure 2A). The nodular surfaces appeared 
to be surrounded by alveolar epithelium. 
Entrapment of cleft-like and tubular spaces 
lined by cuboidal epithelium was noted in the 
interior of the nodules (Figure 2B). At high 
power, there was a proliferation of interlacing 
smooth muscle bundles without cytologic atyp-
ia (Figure 2C). Plump spindle-shaped smooth 
muscle cells with elongated nuclei and eosino-
philic cytoplasm formed anastomosing fasci-
cles. Lack of hypercellularity, moderate-to-
severe cytologic atypia, atypical mitotic figures, 
and coagulative tumor cell necrosis excluded 
the possibility of metastatic leiomyosarcoma. 
There was no morphological evidence of dif-
fuse growth or infiltration of small cells admixed 
with spiral arteriole-like vasculatures, excluding 
the possibility of metastatic endometrial stro-
mal sarcoma.
Immunohistochemical findings
The tumor cells were strongly and diffusely pos-
itive for estrogen receptor (ER; Figure 2D), pro-
gesterone receptor (PR; Figure 2E) and smooth 
muscle actin (SMA; Figure 2F) in all patients. In 
contrast, thyroid transcription factor-1 (TTF-1) 
was present in entrapped bronchiolar epithelial 
cells only (Figure 2G). The Ki-67 labeling index 
was nearly negative (less than 1%) for the 
tumor cells, excluding the possibility of meta-
static leiomyosarcoma or endometrial stromal 
sarcoma. In each patient, these morphologic 
features were the same as those of their previ-
ously resected uterine leiomyomas.
Discussion
Because of the rarity of BML, only a limited 
number of studies have investigated the dis-
ease; its risk factors, related etiology, and clini-
cal behaviors have been poorly studied. How- 
ever, the reported cases share common char-
acteristics. Most included histories of prior 
uterine surgery, including myomectomy and 
hysterectomy, suggesting a clue to the patho-
genesis of BML. While the lungs are known as 
the predominant metastatic site [7, 8], other 
sites, including skin, deep soft tissue, muscle, 
skull, spine and lymph nodes, have been 
reported [9-13]. The interval between surgical 
removal of the uterine leiomyoma and the dis-
covery of extrauterine lesions is approximately 
10 years on average [14, 15]. Consistent with 
previous data, we observed that 10 of 11 
patients underwent uterine surgery and the 
mean interval between the surgery and the 
detection of pulmonary lesions was 8 years. 
However, pulmonary BML and uterine tumor 
are rarely discovered simultaneously, and it can 
be difficult to establish a diagnosis. Further- 
more, if a patient has neither a previous history 
nor significant symptoms of gynecologic dis-
ease, it may be difficult to identify the primary 
origin of the pulmonary tumors.
BML mainly affects sexually mature women 
when hormonal effects are at a maximal level. 
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Most BMLs have been found to express ER and 
PR [12, 16]. Therefore, the lesions are generally 
recognized to be sex hormone responsive. 
Because of natural changes in hormonal levels 
after menopause, BMLs are rarely identified in 
postmenopausal women and are known to 
decrease in size after menopause. Only six 
cases of pulmonary BMLs in postmenopausal 
women have been reported in the literature [5, 
7, 14, 15, 17, 18]. These studies reported that 
the postmenopausal women with pulmonary 
BMLs had no significant symptoms of respira-
tory disease. In contrast, we observed that two 
of three postmenopausal women with pulmo-
nary BML had significant respiratory symptoms 
such as chest pain and coughing. However, the 
presence of respiratory symptoms was not 
associated with clinical status or outcome. In 
all patients reported previously, pulmonary 
lesions were detected several years after hys-
terectomy or myomectomy. In our series, the 
interval between the uterine surgery and the 
diagnosis of BML ranged from 41 months to 19 
years.
There is no standardized treatment for BML 
because of the limited number of reported 
cases. Treatment options include surgical 
resection of pulmonary nodules, BSO and hor-
monal therapy. Some authors have stated that 
BSO should be considered as a primary treat-
ment in premenopausal women [10, 19]. The 
authors of another study also suggested that 
resection should be undertaken whenever pos-
sible in patients with symptomatic metastasis 
[20]. In general, the presence or absence of ER 
and PR plays a key role in their management. 
Removal of estrogen stimulation by oophorec-
tomy or hormonal therapy using a GnRHa, 
SERM, and AI has been suggested as the best 
option for unresectable metastatic lesions [12, 
15, 21]. Clinical evidence of a hormonal influ-
ence is supported by the fact that the pulmo-
nary nodules diminish in size following meno-
pause, during pregnancy and after the with-
drawal of hormonal contraception. In this study, 
surgical resection of pulmonary nodules, BSO, 
and hormonal therapy, as well as a combination 
of BSO and hormonal therapy, were effective in 
controlling BMLs. All but one patient remained 
stable for a median follow-up of 46 months 
after the initiation of therapy. Although this 
period might not be long enough to reach a 
definitive conclusion, taking into account the 
slow-growing nature of a BML, most patients 
with BML treated with either surgical or medi-
cal methods had good outcomes [1, 9-11]. 
Many authors support the idea that patients 
with BML are best managed with a combination 
of surgery for metastatic tumors and hormonal 
therapy [1, 9-11, 19, 20]. When the tumors are 
completely resected, no further treatment may 
be needed. In the event of incomplete surgery, 
it has been reported that hormonal therapy 
achieved good disease control.
However, not all patients seem to respond to 
hormone treatment [22], and side effects 
including flushes, fatigue, and nausea can be 
aggravating. One of our patients refused to 
undergo surgery or receive hormonal therapy 
because of menopausal symptoms. Consequ- 
ently, she died of respiratory failure due to rap-
idly disseminated BML nodules filling up the 
entire lung parenchyma. A small proportion of 
BMLs have been reported to display an aggres-
sive course [23]. A wait-and-see strategy 
appears inappropriate for BML. Depending on 
the extent and location of metastatic lesions 
and the hormonal receptor status, treatment 
should be individualized for each patient. It may 
be possible to discontinue hormonal treatment 
for some time if the tumors are well controlled. 
It also seems possible to restart these agents if 
the tumors begin to increase in size again. 
Importantly, a detailed examination and long-
term follow-up period is recommended to avoid 
under- or overtreatment.
Histologically, pulmonary BML consists of be- 
nign smooth muscle cells that are similar to 
uterine leiomyoma. In our series, all of the 
tumors showed no evidence of high cellularity, 
epithelioid or symplastic patterns, vascular 
invasion, cytological atypia, coagulative tumor 
necrosis, or mitotic figures, excluding the pos-
sibility of malignancy. Their Ki-67 labeling index 
was very low, supporting the low proliferative 
state of these lesions. In addition, the pulmo-
nary nodules contain glandular-appearing str- 
uctures that comprise alveolar or bronchiolar 
epithelium, as observed on histopathology [24, 
25]. These entrapped glandular elements are 
commonly observed in the interior of metastat-
ic nodules, and can cause diagnostic confusion 
[15, 24, 25]. The lack of nuclear atypia and 
strong immunoreactivity for TTF-1 in the epithe-
lial lining preclude the possibility of primary 
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lung cancer and metastatic malignancy. On 
radiographic examinations, the lung lesions are 
typically well-circumscribed, solitary, or multi-
ple nodules ranging from a few millimeters to 
several centimeters in diameter scattered 
among normal interstitium [24]. They usually 
show little change and may even spontaneous-
ly regress [26]. Endobronchial and pleural spar-
ing is characteristic [18]. A previous study 
reported that pulmonary BML presented as 
multiple nodules in 87% of cases (70% bilateral 
nodules and 17% unilateral nodules) or as a 
solitary nodule in 13% of cases [26]. Similarly, 
in our series, it presented in 81.8% of cases as 
multiple bilateral nodules, in 9.1% as multiple 
unilateral nodules and in 18.2% as a single 
nodule.
There is persisting controversy regarding the 
pathogenesis and biology of these lesions. 
Certain researchers hypothesize that BML, 
once termed ‘multiple fibroleiomyomatous ha- 
martoma’, is a type of multiple smooth muscle 
in situ proliferation that is induced by estrogen 
and progesterone. The presence of entrapped 
epithelial elements contributed to this confu-
sion. In contrast, others support the idea that 
BML results from the monoclonal, hematoge-
nous spread of a differentiated uterine leiomy-
oma. Currently, the majority of studies concur 
with BML being a metastatic leiomyoma that 
metastasizes between the uterus and the 
lungs, as all reported cases are in women with 
a previous history of surgical resection for uter-
ine leiomyoma. The patients with single pulmo-
nary nodules or multiple nodular lesions of vari-
ous sizes in both lungs reported in the present 
study had undergone myomectomy or hysterec-
tomy, leading to the vascular spread of uterine 
smooth muscle cells. Hormone receptor posi-
tivity in extrauterine lesions and the response 
to hormone treatment also support this hypoth-
esis. Another possible explanation is that the 
pulmonary lesions actually represent low-grade 
leiomyosarcomas of the uterus with metastatic 
potential [24]. However, the clinical course of 
BML is much less aggressive than a true leio-
myosarcoma [12, 15]. Certain studies have 
reported cases with BML accompanied by mul-
tiple pleural and peritoneal nodules. In addi-
tion, the findings of recent cytogenetic studies 
are also consistent with a monoclonal origin of 
both uterine and pulmonary tumors [4, 27]. All 
of these studies indicate that pulmonary leio-
myomatous nodules are metastatic. However, 
BML has been determined to be a benign 
lesion, because these tumors consist of well-
differentiated, benign-appearing smooth mus-
cle cells with a regular karyotype that lacks 
pleomorphism or mitotic figures. Additional 
investigations are necessary to determine the 
existence of primary pulmonary leiomyoma, 
because leiomyoma arising in men and chil-
dren has been reported as non-metastatic, 
with residual alveoli in the lesions and no vas-
cular tumor embolus in the lungs [27].
The diagnosis of BML can only be made with 
certainty after careful and extensive sampling 
of the primary uterine tumor to exclude small 
foci of sarcoma as well as sampling of the pul-
monary tumor to rule out primary neoplasm. 
Even though it is biologically peculiar, BML 
should continue to be recognized as a distinct 
entity because current morphologic criteria do 
not allow primary uterine tumors to be classi-
fied as smooth muscle tumors of uncertain 
malignant potential even if they have metasta-
sized to the lungs.
In summary, although BML is a rarely reported 
disease, women of reproductive age with a his-
tory of uterine leiomyoma, especially uterine 
tumor surgery, should be considered for possi-
ble diagnosis of pulmonary BML when solitary 
or multiple pulmonary nodules are present. A 
biopsy of multiple lesions should be taken to 
identify the pathological types and sources as 
soon as possible. If the pathological findings of 
the pulmonary nodules reveal a well-differenti-
ated leiomyomatous tumor, careful examina-
tion of the uterus should be performed to iden-
tify the possible primary origin of the metastat-
ic pulmonary lesions. Surgery is the first choice 
for patients who can tolerate the operation; if 
surgery is not a good choice, hormonal therapy 
may be the only effective treatment alternative, 
coupled with monitoring of the hormone levels 
and monitoring for relapse or distant metasta-
sis of BML.
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